RECENT TRENDS IN TREATMENT OF ARRHYTHMIAS
... depolarisation in the cardiac muscle. The most recent antiarrhythmic drugs are included togethier. A little is known about it electrophysiologic properties, and more studies are still needed. Some of them e.g. pranolium may be of help in protection in patients who are at high risk of sudden coronary ...
... depolarisation in the cardiac muscle. The most recent antiarrhythmic drugs are included togethier. A little is known about it electrophysiologic properties, and more studies are still needed. Some of them e.g. pranolium may be of help in protection in patients who are at high risk of sudden coronary ...
Cardiac Resynchronization Therapy
... Cardiac Resynchronization Therapy Cardiac resynchronization therapy (CRT) is a treatment for heart failure that uses an implantable device to improve the pumping efficiency of the heart. In healthy people, the four chambers of the heart contract in synchrony to move blood through the body (people ex ...
... Cardiac Resynchronization Therapy Cardiac resynchronization therapy (CRT) is a treatment for heart failure that uses an implantable device to improve the pumping efficiency of the heart. In healthy people, the four chambers of the heart contract in synchrony to move blood through the body (people ex ...
EFFECT OF SHENMAI INJECTION ON CARDIAC FUNCTION IN
... Objectives To investigate the effect of Shenmai injection on the therapeutic effect and cardiac function and brain natriuretic peptide (BNP) in gerontal patient with chronic heart failure. Methods 64 patients age more than 65 years with chronic heart failure were randomly divided into two groups: th ...
... Objectives To investigate the effect of Shenmai injection on the therapeutic effect and cardiac function and brain natriuretic peptide (BNP) in gerontal patient with chronic heart failure. Methods 64 patients age more than 65 years with chronic heart failure were randomly divided into two groups: th ...
Ventricular assist devices are primarily indicated for either a one or a
... of several factors. These factors include destination therapy, bridge to transplant, bridge to recovery, and eligibility for transplant. Most often, congestive heart failure is the causative force that necessitates the placement of a VAD. Congestive heart failure can be defined as an inability of th ...
... of several factors. These factors include destination therapy, bridge to transplant, bridge to recovery, and eligibility for transplant. Most often, congestive heart failure is the causative force that necessitates the placement of a VAD. Congestive heart failure can be defined as an inability of th ...
non compacted myocardium diagnostic criteria and management
... Occurrence of thrombo embolic events •An aggressive treatment strategy is recommended for high-risk patients, including ICD implantation and early listing for heart transplantation where appropriate •Factors of poor prognosis: Enlarged end-diastolic left ventricular diameter when first measured NYHA ...
... Occurrence of thrombo embolic events •An aggressive treatment strategy is recommended for high-risk patients, including ICD implantation and early listing for heart transplantation where appropriate •Factors of poor prognosis: Enlarged end-diastolic left ventricular diameter when first measured NYHA ...
St. Anthony Hospitals Centura Health: Heart Failure Physician
... collect and publicly report performance data on all coded heart failure discharges. This requirement was established to improve the safety and quality of inpatient care, and to support performance improvement in hospitals. The following Physician-Driven “Core Measures” are based on the American Coll ...
... collect and publicly report performance data on all coded heart failure discharges. This requirement was established to improve the safety and quality of inpatient care, and to support performance improvement in hospitals. The following Physician-Driven “Core Measures” are based on the American Coll ...
Hospital Newsletter Article/Blog Post
... traditional single-chamber ICDs. As a leader in cardiac care, [Hospital name is /we are] now offering the Visia AF MRI™ SureScan® and Visia AF™ implantable cardioverter defibrillators (ICDs), single-chamber ICDs that can treat lifethreatening arrhythmias in the lower chambers of the heart, while als ...
... traditional single-chamber ICDs. As a leader in cardiac care, [Hospital name is /we are] now offering the Visia AF MRI™ SureScan® and Visia AF™ implantable cardioverter defibrillators (ICDs), single-chamber ICDs that can treat lifethreatening arrhythmias in the lower chambers of the heart, while als ...
Treatment of Ischemic Heart Failure With Bone Marrow Cells Does
... In an exploratory analysis, the researchers did find that when LVEF was assessed, patients age 62 years or younger showed a statistically significant effect of therapy. Patients in the BMC group demonstrated an average increase in LVEF of 3.1 percent from baseline to 6 months, whereas patients in t ...
... In an exploratory analysis, the researchers did find that when LVEF was assessed, patients age 62 years or younger showed a statistically significant effect of therapy. Patients in the BMC group demonstrated an average increase in LVEF of 3.1 percent from baseline to 6 months, whereas patients in t ...
Complications of Heart Disease Case Study Answers
... weakness and heart irregularities? One of the major side effects of Lasix is hypokalemia. Mr. Edwards’ symptoms of fatigue, generalized weakness and cardiac irregularities are seen in the patient with hypokalemia. Hypokalemia in patients with heart failure is also problematic as it markedly weakens ...
... weakness and heart irregularities? One of the major side effects of Lasix is hypokalemia. Mr. Edwards’ symptoms of fatigue, generalized weakness and cardiac irregularities are seen in the patient with hypokalemia. Hypokalemia in patients with heart failure is also problematic as it markedly weakens ...
Decision Tree for International
... ESC Criteria for VAD-Eligible Patients1 Patients with >2 months of severe symptoms despite optimal medical and device therapy and more than one of the following: • LVEF<25% and, if measured, peak VO2 <12mL/kg/min • ≥3 HF hospitalizations in previous 12 months without an obvious precipitating cause ...
... ESC Criteria for VAD-Eligible Patients1 Patients with >2 months of severe symptoms despite optimal medical and device therapy and more than one of the following: • LVEF<25% and, if measured, peak VO2 <12mL/kg/min • ≥3 HF hospitalizations in previous 12 months without an obvious precipitating cause ...
Cardiac Failure Protocol
... To confirm the diagnosis of heart failure by electrocardiography where possible. To consider all possible treatment options to improve the quality of life. To promote the use of angiotensin-converting enzyme inhibitors Identification of target population Cardiac failure is a clinical syndrome ...
... To confirm the diagnosis of heart failure by electrocardiography where possible. To consider all possible treatment options to improve the quality of life. To promote the use of angiotensin-converting enzyme inhibitors Identification of target population Cardiac failure is a clinical syndrome ...
PowerPoint File
... ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then oral spironolactone 25 mg daily for 6 months (n = 802) vs. control (n = 801). ...
... ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then oral spironolactone 25 mg daily for 6 months (n = 802) vs. control (n = 801). ...
The Cardiac Cycle
... a. The _____________ _______, or SA node, is the “pace maker of the heart. i. It is located in the superior aspect of the _________ _________ b. It fires electrical signals to the _____________________ ______, or the AV node. i. This sends an electrical signal to the ____________ __ ________ and eve ...
... a. The _____________ _______, or SA node, is the “pace maker of the heart. i. It is located in the superior aspect of the _________ _________ b. It fires electrical signals to the _____________________ ______, or the AV node. i. This sends an electrical signal to the ____________ __ ________ and eve ...
Abstrak_Inahrs_Dr__Indah_Ayu_Pratiwi1
... Objective: Fragmented QRS (FQRS) is a convenient marker of myocardial scar evaluated by 12-lead electrocardiogram (ECG) recording. FQRS is defined as additional spikes within the QRS complex. FQRS was recently correlated with various outcomes in ischemic and nonischemic heart disease. We hypothesize ...
... Objective: Fragmented QRS (FQRS) is a convenient marker of myocardial scar evaluated by 12-lead electrocardiogram (ECG) recording. FQRS is defined as additional spikes within the QRS complex. FQRS was recently correlated with various outcomes in ischemic and nonischemic heart disease. We hypothesize ...
The benefits of CRT for NYHA II-III HF patients with a wide QRS, low
... • Chronic heart failure • LVEF between 36% and 50% • LBBB with QRS ≥ 130 ms • Patient is either: – NYHA Class III OR – NYHA Class II, with hospitalization for HF in the last 12 months OR – NYHA Class II, without hospitalization for HF, but with BNP ≥ 250 pg/ml or NT-proBNP > 1,000 pg/ml • Sinus r ...
... • Chronic heart failure • LVEF between 36% and 50% • LBBB with QRS ≥ 130 ms • Patient is either: – NYHA Class III OR – NYHA Class II, with hospitalization for HF in the last 12 months OR – NYHA Class II, without hospitalization for HF, but with BNP ≥ 250 pg/ml or NT-proBNP > 1,000 pg/ml • Sinus r ...
Long non-coding RNA (lncRNA) LIPCAR predicts survival in heart
... Due to dynamically regulation of the myocardial transcriptome in pathological processes, lncRNAs emerge as new and specific biomarkers for the diagnosis of cardiovascular diseases. Recent studies identified the mitochondria-derived lncRNA LIPCAR as a very promising biomarker for the prognosis of sur ...
... Due to dynamically regulation of the myocardial transcriptome in pathological processes, lncRNAs emerge as new and specific biomarkers for the diagnosis of cardiovascular diseases. Recent studies identified the mitochondria-derived lncRNA LIPCAR as a very promising biomarker for the prognosis of sur ...
multidiciplinary treatment in severe heart failure patients
... Multidiciplinary traetment in severe heart failure patients Background: Heart failure is a severe disease which is associated with significant morbidity including impairment in general activity, well being, leads to frequent hospital admissions and recurrent visits to emergency room and primary care ...
... Multidiciplinary traetment in severe heart failure patients Background: Heart failure is a severe disease which is associated with significant morbidity including impairment in general activity, well being, leads to frequent hospital admissions and recurrent visits to emergency room and primary care ...
Ethical Scenario - My Surgery Website
... job you are required to make a high profile budget decision. The local hospital trust has increased it’s spending on 2 significant areas within cardiology – ICD implantation and cardiac ablation. ICD implantation has been proven to prolong life as well as potentially improve quality of life. It is u ...
... job you are required to make a high profile budget decision. The local hospital trust has increased it’s spending on 2 significant areas within cardiology – ICD implantation and cardiac ablation. ICD implantation has been proven to prolong life as well as potentially improve quality of life. It is u ...
Top 10 Things To Know - Professional Heart Daily
... 1. Recently published trial data and significant changes in the technology available for pacemaker followup, specifically in the area of remote follow-up and monitoring, were considered impactful to prompt this focused update of the 2008 Guidelines for Device-based Therapy of Cardiac Rhythm Abnormal ...
... 1. Recently published trial data and significant changes in the technology available for pacemaker followup, specifically in the area of remote follow-up and monitoring, were considered impactful to prompt this focused update of the 2008 Guidelines for Device-based Therapy of Cardiac Rhythm Abnormal ...
Slide ()
... Hemodynamic responses to pharmacologic interventions in heart failure. The relationships between diastolic filling pressure (preload) and stroke volume (ventricular performance) are illustrated for a normal heart (green line; the Frank-Starling relationship) and for a patient with heart failure due ...
... Hemodynamic responses to pharmacologic interventions in heart failure. The relationships between diastolic filling pressure (preload) and stroke volume (ventricular performance) are illustrated for a normal heart (green line; the Frank-Starling relationship) and for a patient with heart failure due ...
Cardiac Resynchronization Therapy (CRT): Expanding the role of
... University of Ottawa Heart Institute Ottawa, Ontario Canada Cardiac resynchronization therapy (CRT) or biventricular pacing is now demonstrated to be effective therapy for both improvement in cardiac function as well as mortality in certain groups of patients with LV dysfunction. First studies in su ...
... University of Ottawa Heart Institute Ottawa, Ontario Canada Cardiac resynchronization therapy (CRT) or biventricular pacing is now demonstrated to be effective therapy for both improvement in cardiac function as well as mortality in certain groups of patients with LV dysfunction. First studies in su ...
INAHRS3
... Cardiac resynchronization therapy (CRT) has been demonstrated as a beneficial therapy option in certain subgroups of chronic heart failure (HF) patients by improving left ventricular (LV) function, survival, and symptoms. Some group of patient show such important clinical improvement and reverse rem ...
... Cardiac resynchronization therapy (CRT) has been demonstrated as a beneficial therapy option in certain subgroups of chronic heart failure (HF) patients by improving left ventricular (LV) function, survival, and symptoms. Some group of patient show such important clinical improvement and reverse rem ...
INAHRS1
... Cardiac resynchronization therapy (CRT) has been demonstrated as a beneficial therapy option in certain subgroups of chronic heart failure (HF) patients by improving left ventricular (LV) function, survival, and symptoms. Some group of patient show such important clinical improvement and reverse rem ...
... Cardiac resynchronization therapy (CRT) has been demonstrated as a beneficial therapy option in certain subgroups of chronic heart failure (HF) patients by improving left ventricular (LV) function, survival, and symptoms. Some group of patient show such important clinical improvement and reverse rem ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.